Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chemotherapy-Induced Nausea and Vomiting Clear all
Completed Phase 2 Interventional Results available

Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting

NCT00787566
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Intranasal granisetron
Drug
Lead sponsor
Shin Nippon Biomedical Laboratories, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
The Study Is Managed by Kendle International, in Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 2 Interventional

Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy

NCT00104403
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting
Interventions
GW679769, Dexamethasone, Ondansetron Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
47
States / cities
Birmingham, Alabama • Corona, California • Greenbrae, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Not applicable Interventional Results available

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

NCT01490060
View directory record Official record
Conditions
Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy, Adverse Effects of Medical Drugs
Interventions
Fosaprepitant, Dexamethasone, 5HT3 receptor antagonist, Ifosfamide-based chemotherapy (AI), Doxorubicin, Mesna, Ifosfamide, Vincristine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

NCT01339260
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Netupitant and Palonosetron, Palonosetron, Dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
1,455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
28
States / cities
Anniston, Alabama • Muscle Shoals, Alabama • Hot Springs, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Not applicable Interventional Results available

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

NCT00343863
View directory record Official record
Conditions
Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
palonosetron hydrochloride, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications, ondansetron hydrochloride, survey administration
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jul 23, 2026, 2:22 PM EDT
Recruiting Not applicable Interventional

Serious Gaming for Chemotherapy-induced Nausea and Vomiting

NCT05838638
View directory record Official record
Conditions
Neoplasms, Chemotherapy-induced Nausea and Vomiting
Interventions
eSSET-CINV
Behavioral
Lead sponsor
University of Central Florida
Other
Eligibility
60 Years and older
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community-Led Action Research in Oncology: Improving Symptom Management

NCT03208816
View directory record Official record
Conditions
Chemotherapy-induced Neutropenia, Chemotherapy-induced Nausea and Vomiting, Anxiety, Depression, Fatigue, Neoplasms
Interventions
symptom management program for chemotherapy patients
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Jul 23, 2026, 2:22 PM EDT
Completed No phase listed Observational

A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients

NCT01757210
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Not listed
Lead sponsor
West Virginia University Healthcare
Other
Eligibility
1 Year to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant

NCT03097588
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Netupitant, Palonosetron Hydrochloride, Questionnaire Administration
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers

NCT02382666
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting

NCT02517021
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting
Interventions
Pro-netupitant/Palonosetron, Netupitant/Palonosetron, Dexamethasone
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
11
States / cities
Santa Monica, California • Whittier, California • Grand Junction, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years

NCT01596400
View directory record Official record
Conditions
Chemotherapy Induced Nausea and Vomiting
Interventions
granisetron transdermal system, Granisetron IV
Drug
Lead sponsor
Kyowa Kirin Pharmaceutical Development Ltd
Industry
Eligibility
13 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2024 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 3 Interventional Results available

A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.

NCT00601172
View directory record Official record
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Casopitant, Dexamethasone, Placebo, Ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
23
States / cities
Hot Springs, Arkansas • Corona, California • Fountain Valley, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Jul 23, 2026, 2:22 PM EDT
Terminated Phase 2 Interventional Results available

Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab

NCT00636805
View directory record Official record
Conditions
Brain Cancer
Interventions
Palonosetron (Aloxi) and Dexamethasone
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Jul 23, 2026, 2:22 PM EDT
Not listed Phase 4 Interventional

Safety Study of Repeat Doses of SUSTOL in Adults

NCT05434663
View directory record Official record
Conditions
Chemotherapy-Induced Nausea and Vomiting (CINV)
Interventions
SUSTOL
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Hattiesburg, Mississippi • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Jul 23, 2026, 2:22 PM EDT
Recruiting Phase 4 Interventional

BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron

NCT04150614
View directory record Official record
Conditions
Nausea With Vomiting Chemotherapy-Induced
Interventions
Granisetron Transdermal Patch, Intravenous Dexamethasone, Ondansetron
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 23, 2026, 2:22 PM EDT
Recruiting No phase listed Observational

Evaluating the Association Among Changes in Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer

NCT05417867
View directory record Official record
Conditions
Chemotherapy-Related Nausea and/or Vomiting, Early Stage Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Interventions
Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 2 Interventional

Ginger Control of Chemotherapy Induced Nausea and Vomiting

NCT00065221
View directory record Official record
Conditions
Nausea, Vomiting, Chemotherapy
Interventions
Ginger
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
5
States / cities
South Bend, Indiana • Ann Arbor, Michigan • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2008 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 2 Interventional

Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy

NCT00003817
View directory record Official record
Conditions
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
dolasetron mesylate, granisetron hydrochloride, ondansetron, tropisetron, quality-of-life assessment
Drug · Procedure
Lead sponsor
Gary Morrow
Other
Eligibility
18 Years to 120 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
2
States / cities
Hackensack, New Jersey • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Jul 23, 2026, 2:22 PM EDT
Terminated Not applicable Interventional

The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and Vomiting

NCT04478630
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting

NCT01031498
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Chemotherapy-induced Nausea and Vomiting
Interventions
Ondansetron, Palonosetron
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2012 · Synced Jul 23, 2026, 2:22 PM EDT
Not listed No phase listed Observational

ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial

NCT02016807
View directory record Official record
Conditions
Oral Mucositis, Nausea, Vomiting, Diarrhea
Interventions
ProThelial
Device
Lead sponsor
Ashley Downs Bioscience
Industry
Eligibility
18 Years to 95 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Foster, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Jul 23, 2026, 2:22 PM EDT
Terminated Phase 4 Interventional

Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting

NCT05590923
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
OLA group: Olanzapine, DEX group: Dexamethasone
Drug
Lead sponsor
The Guthrie Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Sayre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant

NCT02285647
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant - Oral, Rolapitant - IV
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Jul 23, 2026, 2:22 PM EDT